Effectiveness of risk communication interventions on the medical follow-up of youth treated with antidepressants

• Published in: Psychiatry research 2013-10, Vol.209 (3), p.471-478
• Main Authors: Cloutier, Anne-Marie, Greenfield, Brian, Lavoie, Annie, Lynd, Larry D, Tournier, Marie, Brabant, Marie-Josée, Moride, Yola
• Format: Article
• Language: English
• Subjects: Adolescent; Adolescents; Antidepressants; Antidepressive Agents - therapeutic use; Biological and medical sciences; Child; Children; Communication; Depression - drug therapy; Depression - psychology; Female; Follow-Up Studies; Humans; Male; Medical follow-up; Medical sciences; Neuropharmacology; Pharmacology. Drug treatments; Practice guidelines; Psychiatry; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psychology. Psychoanalysis. Psychiatry; Psychopharmacology; Retrospective Studies; Risk communication; Suicide; Young Adult
• ISSN: 0165-1781; 1872-7123
• DOI: 10.1016/j.psychres.2012.12.029

Abstract Following reports of a potential association between antidepressants (ADs) and suicidal behaviour in youth, regulatory warnings were issued in May 2004, and clinical recommendations on medical follow-up were published in November 2007. Our study aimed at assessing the association between these communication interventions and medical follow-up of children (age 10–14) and adolescents (age 15–19) who initiate an AD treatment. A retrospective cohort study (1998–2008) was conducted among youth members of the Quebec public drug plan. Study outcomes consisted of adequate follow-up practice, defined as at least 1 medical visit per month during the first 3 months of treatment. The effect of each intervention on follow-up practices was determined through multivariate logistic regression analysis. The cohort included 4576 children and 12,419 adolescents. Two thirds of both children and adolescents had at least one medical visit during the first trimester of treatment, but only 20% had a frequency of at least one visit per month (i.e. adequate). The occurrence and frequency of visits did not change after either the warning nor the publication of the guidelines. Further interventions designed to optimize monitoring practices should be envisaged.